Globe Artichoke

This is artichoke’s best-evidenced use. A meta-analysis of 9 RCTs (702 subjects) found artichoke extract lowered total cholesterol by about 17.6 mg/dL, LDL by about 14.9 mg/dL and triglycerides by about 9.2 mg/dL, with no change in HDL, and a larger effect in people with higher baseline LDL ^{1Reference 1Sahebkar A et al. · 2018Meta-analysisLipid-lowering activity of artichoke extracts — systematic review and meta-analysisView study →}. A later dose-response meta-analysis of 14 studies reproduced the direction and magnitude (TC, LDL and TG all down roughly 17 mg/dL) ^{2Reference 2Shahinfar H et al. · 2021Meta-analysisEffects of artichoke leaf extract supplementation or artichoke juice on lipid profile — systematic review and dose-response meta-analysis of randomised controlled trialsView study →}, and a 2025 cardiometabolic synthesis again confirmed reductions in TC, LDL and TG ^{3Reference 3Jafari A et al. · 2025Artichoke and cardiometabolic health — systematic and meta-analytic synthesisView study →}. Individual double-blind RCTs support this: 1,800 mg/day of a dry leaf extract cut cholesterol in hyperlipoproteinaemic patients ^{6Reference 6Englisch W et al. · 2000RCTEfficacy of artichoke dry extract in patients with hyperlipoproteinemia — randomised, double-blind, placebo-controlled trialView study →}, and 1,280 mg/day lowered total cholesterol in otherwise-healthy hypercholesterolaemic adults ^{5Reference 5Bundy R et al. · 2008RCTArtichoke leaf extract reduces plasma cholesterol in otherwise healthy hypercholesterolemic adults — randomised, double-blind, placebo-controlled trialView study →}. The Cochrane review that first assessed this indication was formally withdrawn in 2016 — for editorial-priority reasons, not because the evidence was overturned ^{4Reference 4Wider B et al. · 2013Systematic reviewArtichoke leaf extract for treating hypercholesterolaemia — Cochrane systematic review (pub3)View study →}. Mechanistically, artichoke extract inhibits hepatic cholesterol biosynthesis from acetate in cultured hepatocytes, an effect traced largely to luteolin ^{7Reference 7Gebhardt R · 1998In vitroInhibition of cholesterol biosynthesis in primary cultured rat hepatocytes by artichoke extracts — in vitroView study →}, and increases biliary cholesterol excretion via its choleretic action ^{15Reference 15Kirchhoff R et al. · 1994RCTIncrease in choleresis by means of artichoke extract — randomised placebo-controlled double-blind crossover studyView study →}.

Gap: effect sizes are modest and heterogeneous between products; trials are short (6–12 weeks) with no cardiovascular-outcome data, and the boiled edible head has not been shown to reproduce the extract’s effect.

The historic “liver tonic” reputation now has controlled human support in the context of fatty-liver disease. A meta-analysis of 5 RCTs (333 NAFLD patients) found ALE significantly reduced ALT and AST alongside total cholesterol, LDL and triglycerides ^{8Reference 8Kamel AM et al. · 2022Meta-analysisTherapeutic potential of artichoke in the treatment of fatty liver — systematic review and meta-analysis of randomised controlled trialsView study →}, and a separate meta-analysis of 8 trials confirmed the fall in liver enzymes, most clearly in NAFLD and overweight subjects ^{9Reference 9Moradi S et al. · 2021Meta-analysisEffects of Cynara scolymus L. supplementation on liver enzymes — systematic review and meta-analysisView study →}. A pilot double-blind RCT in 100 NAFLD patients reported reduced liver size, improved hepatic blood flow and lower ALT/AST on ultrasound and serology after two months of 600 mg/day ^{10Reference 10Panahi Y et al. · 2018RCTEfficacy of artichoke leaf extract in non-alcoholic fatty liver disease — pilot double-blind randomised controlled trialView study →}. A 2026 placebo-controlled trial in pre-bariatric patients used FibroScan to confirm reduced hepatic steatosis and liver volume within weeks — though, unusually, AST rose in that obese population, a signal worth noting ^{11Reference 11Holländer S et al. · 2026RCTArtichoke leaf extract reduces steatosis and decreases liver size in pre-bariatric patients (SteatoChoke) — randomised placebo-controlled trialView study →}. The preclinical rationale is antioxidant and choleretic: cynarin and leaf polyphenols protect hepatocytes and support bile flow ^{7,15Reference 7Gebhardt R · 1998In vitroInhibition of cholesterol biosynthesis in primary cultured rat hepatocytes by artichoke extracts — in vitroView study →Reference 15Kirchhoff R et al. · 1994RCTIncrease in choleresis by means of artichoke extract — randomised placebo-controlled double-blind crossover studyView study →}.

Gap: trials are short and mostly small/pilot-grade, endpoints are surrogate (enzymes, ultrasound/FibroScan) rather than biopsy, and the divergent transaminase response in obese patients ^{11Reference 11Holländer S et al. · 2026RCTArtichoke leaf extract reduces steatosis and decreases liver size in pre-bariatric patients (SteatoChoke) — randomised placebo-controlled trialView study →} means the hepatic effect may not be uniform across populations.

Artichoke’s bitter, bile-stimulating action maps onto indigestion, and this is backed by a proper trial. A double-blind, placebo-controlled, multicentre RCT in 247 patients with functional dyspepsia found ALE (640 mg three times daily) produced significantly greater symptom improvement than placebo over six weeks, with better quality-of-life scores ^{12Reference 12Holtmann G et al. · 2003RCTEfficacy of artichoke leaf extract in functional dyspepsia — six-week placebo-controlled, double-blind, multicentre randomised trialView study →}. An earlier large open study (516 participants, 454 completers) had reported dose-dependent symptom relief ^{13Reference 13Marakis G et al. · 2002Artichoke leaf extract reduces mild dyspepsia in an open studyView study →}, and a subset analysis extended the benefit to overlapping irritable-bowel symptoms ^{14Reference 14Bundy R et al. · 2004Artichoke leaf extract reduces symptoms of irritable bowel syndrome and improves quality of life — subset analysisView study →}. The plausible mechanism is increased bile secretion (see Choleretic), which aids fat digestion and gastric emptying.

Gap: the pivotal evidence is a single rigorous RCT; the supporting studies are open-label or surveillance-grade and prone to placebo response, which runs high in dyspepsia.

The claim that artichoke stimulates bile is one of the few herbal choleretic effects measured directly in humans. In a randomised, placebo-controlled, double-blind crossover pilot (n=20), a single intraduodenal dose of standardised extract raised measured bile secretion by roughly 127% at 30 minutes and about 150% at 60 minutes versus placebo ^{15Reference 15Kirchhoff R et al. · 1994RCTIncrease in choleresis by means of artichoke extract — randomised placebo-controlled double-blind crossover studyView study →}. This choleresis underpins both the dyspepsia benefit (better fat digestion) and part of the cholesterol effect (greater biliary cholesterol excretion) ^{15Reference 15Kirchhoff R et al. · 1994RCTIncrease in choleresis by means of artichoke extract — randomised placebo-controlled double-blind crossover studyView study →}. The active principles are the caffeoylquinic acids, above all cynarin, concentrated in the leaf.

Gap: the direct human evidence is a single small pilot using an intraduodenal dose; the effect of ordinary oral dosing over time on bile dynamics is inferred rather than measured. This action is also the basis for the gallstone caution (see Safety).

Artichoke is polyphenol-rich, and antioxidant activity is well demonstrated in the lab but only weakly in people. A meta-analysis of animal studies found extract supplementation raised superoxide dismutase, catalase, glutathione and glutathione peroxidase and lowered malondialdehyde (a lipid-peroxidation marker) in liver and plasma; the same review noted human trials showed no change or only slight improvement in antioxidant status ^{16Reference 16Salekzamani S et al. · 2019Meta-analysisThe antioxidant activity of artichoke (Cynara scolymus) — systematic review and meta-analysis of animal studiesView study →}. In vitro, chlorogenic acid, caffeic acid and related caffeoylquinic acids scavenge reactive oxygen species and inhibit LDL oxidation in endothelial cells and monocytes ^{17Reference 17Zapolska-Downar D et al. · 2002In vitroProtective properties of artichoke against oxidative stress induced in cultured endothelial cells and monocytes — in vitroView study →}. A small RCT in rowers found leaf extract shifted redox markers modestly after exhaustive exercise [not scored separately here].

Gap: the convincing effects are in animals and cell systems; human data are limited and inconsistent, so the antioxidant label is mechanistically real but not clinically established.

Evidence here is genuinely mixed rather than positive-with-caveats. A meta-analysis of 9 RCTs found artichoke significantly lowered fasting blood sugar (by about 5.3 mg/dL) but produced no significant change in fasting insulin, HOMA-IR or HbA1c ^{18Reference 18Jalili C et al. · 2020Meta-analysisEffects of Cynara scolymus L. on glycemic indices — systematic review and meta-analysis of randomised clinical trialsView study →}. The 2025 cardiometabolic synthesis similarly reported reduced insulin and HOMA-IR but no effect on fasting glucose or HbA1c — a partly contradictory picture across pooled analyses ^{3Reference 3Jafari A et al. · 2025Artichoke and cardiometabolic health — systematic and meta-analytic synthesisView study →}. The frequently repeated claim that chlorogenic acid regulates blood glucose by inhibiting glucose-6-phosphatase is constituent-level inference, not demonstrated for the whole herb in humans.

Gap: the glucose signal is small, endpoints disagree between meta-analyses, and there is no consistent effect on the markers (HbA1c, insulin resistance) that matter most for diabetes.

Beyond lipids, artichoke may act directly on the vessel wall. In a small clinical trial, 20 mL/day of artichoke juice improved brachial flow-mediated vasodilation — a measure of endothelial function — in hyperlipaemic patients ^{21Reference 21Lupattelli G et al. · 2004Clinical trialArtichoke juice improves endothelial function in hyperlipemia — clinical trialView study →}. The mechanism is mapped in human cells: leaf flavonoids up-regulate endothelial nitric-oxide synthase (eNOS), raising nitric-oxide production ^{22Reference 22Li H et al. · 2004In vitroFlavonoids from artichoke (Cynara scolymus L.) up-regulate endothelial-type nitric-oxide synthase gene expression in human endothelial cells — in vitroView study →}, while cynarin, cyanidin and luteolin down-regulate the pro-inflammatory inducible NOS (iNOS) in coronary smooth-muscle cells ^{23Reference 23Xia N et al. · 2014In vitroArtichoke, cynarin and cyanidin downregulate the expression of inducible nitric oxide synthase in human coronary smooth muscle cells — in vitroView study →}. Extracts also blunt reactive-oxygen and oxidised-LDL damage in endothelial cells ^{17Reference 17Zapolska-Downar D et al. · 2002In vitroProtective properties of artichoke against oxidative stress induced in cultured endothelial cells and monocytes — in vitroView study →}.

Gap: the human evidence is one small, short juice study; the rest is cell-culture mechanism, so the vascular benefit is promising but not yet demonstrated at scale or with clinical endpoints.

The blood-pressure claim is the weakest of artichoke’s cardiometabolic uses. A meta-analysis of 8 RCTs found no overall effect on systolic or diastolic pressure; only a subgroup analysis restricted to hypertensive patients (and to 12-week interventions) showed reductions of a few mmHg ^{19Reference 19Moradi M et al. · 2021Meta-analysisEffects of artichoke on blood pressure — systematic review and meta-analysisView study →}. A dedicated RCT in hypertensive patients on captopril found improvement in BMI but no clear added blood-pressure benefit from artichoke ^{20Reference 20Ardalani H et al. · 2020RCTThe effect of Cynara scolymus on blood pressure and BMI in hypertensive patients — randomised, double-blind, placebo-controlled clinical trialView study →}. The in vitro ACE-inhibition finding the page’s “mild ACE inhibitor” tag rests on is a single cell-free enzyme assay, not a clinical effect.

Gap: the pooled effect is null except in a post-hoc hypertensive subgroup; the mechanistic ACE claim is in vitro only, and no trial establishes artichoke as a stand-alone antihypertensive.

Artichoke leaf extract is well tolerated in trials; the reported adverse effects are mild and gastrointestinal — transient diarrhoea, abdominal spasm, nausea and heartburn — with allergic reactions also possible. Because artichoke belongs to the Asteraceae (Compositae) family, people allergic to daisies, ragweed, marigold or chrysanthemum can react to it. Its cholagogue action makes it a genuine risk in obstructive biliary disease: pharmacopoeial monographs contraindicate artichoke leaf in bile-duct obstruction and advise caution with gallstones, since stimulating bile flow can dislodge stones into the ducts. One recent RCT in obese pre-bariatric patients unexpectedly saw a rise in aspartate aminotransferase, so the usual liver-enzyme-lowering effect may not hold in every population ^{11Reference 11Holländer S et al. · 2026RCTArtichoke leaf extract reduces steatosis and decreases liver size in pre-bariatric patients (SteatoChoke) — randomised placebo-controlled trialView study →}.

Interactions have not been systematically assessed here: no clinically demonstrated CYP450 or drug interaction was found in the reviewed literature, though an additive effect with lipid-lowering and antihypertensive medication is plausible in theory and untested — do not read either safety or a specific interaction into the absence of data.